North America Sickle Cell Disease Market, By Disease Type (Sickle Cell Anemia, Sickle Beta Thalassemia, Sickle Hemoglobin C Disease), By Drug Type (Hydroxyurea, L-glutamine, Crizanlizumab, Pain-relievers, Voxelotor, Others), By Distribution Channel (Hospi

North America Sickle Cell Disease Market, By Disease Type (Sickle Cell Anemia, Sickle Beta Thalassemia, Sickle Hemoglobin C Disease), By Drug Type (Hydroxyurea, L-glutamine, Crizanlizumab, Pain-relievers, Voxelotor, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Sickle Cell Disease (SCD) is a group of inherited red blood cell disorders. Red blood cells contain hemoglobin, a protein that carries oxygen. Healthy red blood cells are round, and they move through small blood vessels to carry oxygen to all parts of the body. In someone who has SCD, the hemoglobin is abnormal, which causes the red blood cells to become hard and sticky and look like a C-shaped farm tool called a “sickle.” Sickle cells die early, which causes a constant shortage of red blood cells. Also, when they travel through small blood vessels, they get stuck and clog the blood flow. This can cause pain and other serious complications (health problems) such as infection, acute chest syndrome, and stroke. Thus, the introduction of advanced products in the market is expected to drive the growth of the North America sickle cell disease market over the forecast period.

Market Dynamics

The key players in the pharmaceutical industry are focusing on the development of technologically advanced drugs for the treatment of sickle cell disease. Thus, the introduction of such advanced products in the market is expected to the drive growth of the North America sickle cell disease market over the forecast period. F006F r instance, on June 21, 2023, bluebird bio, Inc., a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) for priority review. Lovo-cel is a potentially transformative one-time gene therapy for individuals living with Sickle Cell Disease (SCD) for ages 12 and older who have a history of Vaso-occlusive Events (VOEs). It is specifically designed to treat the underlying cause of SCD through the addition of a functional gene that enables the production of anti-sickling adult hemoglobin and is the most deeply studied gene therapy in development for this disease.

Key features of the study:

• This report provides an in-depth analysis of the North America sickle cell disease market and provides market size (US$ Million) and Compound Annual Growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the North America sickle cell disease market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Novartis International AG, Bristol-Myers Squibb Company, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., IMARA, , bluebird bio, Inc., CRISPR Therapeutics, Scribe Therapeutics Inc., Fulcrum Therapeutics, Inc., HPC International, Editas Medicine, Inc., Nicox SA, Fera Pharmaceuticals, and Tessera Therapeutics
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The North America sickle cell disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America sickle cell disease market

Detailed Segmentation:

• By Disease Type:
• Sickle Cell Anemia
• Sickle Beta Thalassemia
• Sickle Hemoglobin C Disease
• By Drug Type:
• Hydroxyurea
• L-glutamine
• Crizanlizumab
• Pain-relievers
• Voxelotor
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Country:
• U.S.
• Canada
• Company Profiles
• Novartis International AG
• Bristol-Myers Squibb Company
• Global Blood Therapeutics, Inc.
• Pfizer Inc.
• Emmaus Life Sciences, Inc.
• ADDMEDICA
• Sangamo Therapeutics, Inc.
• Acceleron Pharma, Inc.
• Agios Pharmaceuticals, Inc.
• Chiesi Farmaceutici S.p.A.
• Vertex Pharmaceuticals, Inc.
• IMARA, Inc.
• bluebird bio, Inc.
• CRISPR Therapeutics
• Scribe Therapeutics Inc.
• Fulcrum Therapeutics, Inc.
• HPC International
• Editas Medicine, Inc.
• Nicox SA
• Fera Pharmaceuticals
• Tessera Therapeutics